{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-042410","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.249998+00:00","generated_at":"2026-06-11T10:58:54.555511+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Clearside Q2 net loss $9.1M; Phase 2b ODYSSEY enrollment underway, topline Q3 2024","bullets":["Net loss $9.1M ($0.15/share) vs $7.8M ($0.13) prior year; cash $35.0M, operations funded into Q3 2024.","Phase 2b ODYSSEY trial for CLS-AX in wet AMD actively enrolling at ~30 U.S. sites; topline data expected Q3 2024.","Partner Arctic Vision's NDA accepted in Australia for Arcatus (suprachoroidal treatment of uveitic macular edema).","R&D expenses $4.9M (down from $5.4M); license revenue $1.0M (up from $0.4M).","Board Chair changed to Clay B. Thorp; Scientific Advisory Board expanded with three new members."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-042410","json":"https://secwatch.observer/filing/0000950170-23-042410.json","markdown":"https://secwatch.observer/filing/0000950170-23-042410.md","text":"https://secwatch.observer/filing/0000950170-23-042410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023042410/0000950170-23-042410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023042410/clsd-20230814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T10:58:54.555511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d844f9930f97b35e9dfb77af1cb34b6c40ec3871","claim":"Clearside Biomedical, Inc. reported the second quarter ended June 30, 2023 results: revenue $1.0 million.","evidence_excerpt":"input on the Company’s research and development programs. Second Quarter 2023 Financial Results • License Revenue: License and other revenue for the second quarter of 2023 was $1.0 million, compared to $0.4 million for the second quarter of 2022. • Cost of Goods Sold: Cost of Goods Sold for the second quarter of 2023 was $0.2 million, compared to $0 for the second","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1539029/000095017023042410/0000950170-23-042410-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$1.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}